The verdict
Our read at a glance.
Whether historical AOD-9604 obesity-development evidence and growth-hormone-fragment biology support current weight-management, body-composition, or wellness claims.
- The signal
- FDA's 2024 PCAC briefing evaluated AOD-9604 free base and AOD-9604 acetate in the 503A bulk-substance context and states that the larger historical OPTIONS obesity study did not show a significant primary-endpoint weight-loss difference versus placebo. ANZCTR documents the OPTIONS trial registration, but this source set does not cite posted trial results.
- The unknown
- Whether any well-characterized AOD-9604 product has clinically meaningful modern obesity or body-composition outcome evidence, and how current compounded, research-use, or internet-market products relate to studied material.
- Our read
- A safety/regulatory watch because the public claim space is much larger than the direct human evidence. AOD-9604 free base/acetate, LAT8881 non-obesity registry contexts, AOD9401, native hGH fragments, full hGH, compounded products, research-use products, and internet-market products are separate evidence categories and should not be treated as equivalent.
The mechanism
How it works.
AOD-9604 is a synthetic peptide copying the tail end (the C-terminal region) of human growth hormone, the part linked to fat metabolism rather than growth. The idea is that this fragment triggers fat cells to break down stored fat and burn it, without the blood-sugar and IGF-1 effects of the full growth-hormone molecule. The fat-burning mechanism comes mainly from animal and cell work, and a larger human obesity trial did not beat placebo, so it has not been shown to drive meaningful fat loss in people.
Safety & regulatory boundary
The consequential part.
FDA lists AOD-9604 among nominated-but-withdrawn bulk substances that may present significant safety risks and identified potential immunogenicity, peptide impurity/API characterization issues, limited safety information, and unclear causality for serious adverse events. This is not an FDA approval document or a global legal-status conclusion.
What's next
What we're watching.
FDA compounding-status updates, independent peer-reviewed clinical outcomes, product characterization standards, and clearer safety reporting. Date-limited checks found no direct AOD-9604 obesity record in ClinicalTrials.gov; LAT8881 registry records are non-obesity contexts and are not treated as public evidence for this memo.
Context
Why this is discussed.
It is often promoted with a simple growth-hormone-fragment weight-control story, while the public evidence base is mostly older development context, regulatory review, identity records, and nonhuman or analytical literature.
The evidence base
31 cited references.
Regulatory & labels6
U.S. Food and Drug Administration · 2024-11-05
U.S. Food and Drug Administration · 2024-12-04
U.S. Food and Drug Administration · Current FDA page
World Anti-Doping Agency · 2013-04-22
World Anti-Doping Agency · Effective 2026-01-01
Therapeutic Goods Administration · 2015-03-19
Peer-reviewed journals3
Stier, Vos, and Kenley · 2013
Indexed literature (PubMed)18
Wilding · 2004
Valentino, Lin, and Waldman · 2010
Bray and Greenway · 2007
Halford · 2006
Jensen · 2006
Khan et al. · 2012
Wu and Ng · 1993
Wijaya and Ng · 1993
Natera, Jiang, and Ng · 1994
Heffernan et al. · 2000
Ng et al. · 2000
Ng et al. · 2000
Heffernan et al. · 2001
Heffernan et al. · 2001
Kwon and Park · 2015
Cox et al. · 2015
Orlovius et al. · 2013
Sponsor & other sources4
Australian New Zealand Clinical Trials Registry · Registered 2005; last updated 2007
National Library of Medicine · Record modified 2025
FDA / NIH NCATS · Current database page
NIH / NCATS · Current database page
Keep reading